Back to Search
CHARLES DRESCHER, MD
MD
Specialist
NPI: 1710939855IndividualAccepts Medicare
Specialties, Licenses & Credentials
SpecialistPrimary
Specialist
Code: 174400000X
MD00026438(WA)
Education
UNIVERSITY OF MICHIGAN MEDICAL SCHOOL
Class of 1982
Research & Publications (20)
Compliance of average- and intermediate-risk women to semiannual ovarian cancer screening.
PMID 15066925·Cancer Epidemiol Biomarkers Prev·2004
3-trial
Reported ovarian cancer screening among a population-based sample in Washington state.
PMID 10862845·Obstet Gynecol·2000
8-other
Specific p38 inhibition in stimulated endothelial cells: a possible new anti-inflammatory strategy after hypothermia and rewarming.
PMID 19576293·Vascul Pharmacol·2009
4-observational
Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses.
PMID 19491256·Cancer Res·2009
7-preclinical
Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.
PMID 19423517·Cancer Epidemiol Biomarkers Prev·2009
8-other
Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers.
PMID 19422301·OMICS·2009
8-other
Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries.
PMID 19390579·PLoS One·2009
8-other
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash.
PMID 19162309·Gynecol Oncol·2009
3-trial
Quality assessment and data analysis for microRNA expression arrays.
PMID 19103660·Nucleic Acids Res·2009
7-preclinical
Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer.
PMID 18768519·Cancer Epidemiol Biomarkers Prev·2008
8-other
DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma.
PMID 18757082·Gynecol Oncol·2008
8-other
Circulating microRNAs as stable blood-based markers for cancer detection.
PMID 18663219·Proc Natl Acad Sci U S A·2008
7-preclinical
Systematic evaluation of candidate blood markers for detecting ovarian cancer.
PMID 18612378·PLoS One·2008
8-other
Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains.
PMID 18560578·PLoS One·2008
8-other
Potential and limitations in early diagnosis of ovarian cancer.
PMID 18546614·Adv Exp Med Biol·2008
6-review
Robotic surgery in gynecologic oncology: program initiation and outcomes after the first year with comparison with laparotomy for endometrial cancer staging.
PMID 18538151·Am J Obstet Gynecol·2008
4-observational
Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma.
PMID 17671125·Clin Cancer Res·2007
4-observational
Changes in cancer worry associated with participation in ovarian cancer screening.
PMID 17225260·Psychooncology·2007
2-rct
Development of an ovarian cancer symptom index: possibilities for earlier detection.
PMID 17154394·Cancer·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1101 MADISON ST, SUITE 1500
SEATTLE, WA 98104 - Phone
- (206) 215-3200
Quick Facts
- NPI
- 1710939855
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 44
- Publications
- 20
Are you this provider?
Claim Your Profile